Novartis bets a billion

In a deal that could hit just shy of $1 billion, Antisoma plc
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
LONDON, U.K.—In a deal that could hit just shy of $1 billion, Antisoma plc announced it has signed an exclusive global licensing agreement with Novartis for AS1404, a vascular disrupting agent that is currently undergoing clinical testing. Aside from immediate and near-term payments, Novartis will also fund and conduct all future development, as well as paying Antisoma various milestone and royalty payments.
 
"This deal provides both extra resources and new strategic options for Antisoma," says Glyn Edwards, Antisoma CEO. "We plan to use it as a springboard to further expand our pipeline and to exploit the value in our present portfolio. We now have an excellent opportunity to gain direct involvement in selling our own products."
 
The move will help Novartis expand its oncology pipeline, further entrenching the company in a competitive cancer therapeutics market that is expected to top $89 billion by 2011, according to a recent report by Kalorama Information.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue